Specifically, the preventive treatment with octreotide 10 mg/28 days i.m. in the eight enrolled patients with MEN1, panNET < 2 cm, and abnormal biomarkers at baseline (increased levels of glucagon in 7/8 and of somatostatin in 1/8) led to a reduction in tumor secretory activity, with normalization of PP, glucagon, and somatostatin values, as well as maintenance of disease stability [93]. The gene discussed is MEN1; the disease is neoplasm.